Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Vigil Neuroscience Inc ( (VIGL) ).
Vigil Neuroscience, Inc. has announced the FDA’s removal of the partial clinical hold on its Phase 1 trial of VG-3927, potentially advancing Alzheimer’s treatment. The company’s interim data suggests safety, tolerability, and once-daily dosing of VG-3927, alongside positive biomarker responses. This regulatory milestone enables further exploration of VG-3927’s full pharmacology, with complete Phase 1 data expected in early 2025, marking a significant step in the development of novel therapies for neurodegenerative diseases.
For an in-depth examination of VIGL stock, go to TipRanks’ Stock Analysis page.
